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Regulatory T cells (Tregs) expressing FOXP3 are essential for the maintenance of self-tolerance and are deﬁ-
cient inmanycommonautoimmunediseases. Immune tolerance ismaintained inpart by IL-2anddeﬁciencies
in the IL-2 pathway cause reduced Treg function and an increased risk of autoimmunity. Recent studies
expanding Tregs in vivo with low-dose IL-2 achieved major clinical successes highlighting the potential to
optimize this pleiotropic cytokine for inﬂammatory and autoimmune disease indications. Here we compare
the clinically approved IL-2 molecule, Proleukin, with two engineered IL-2 molecules with long half-lives
owing to their fusion in monovalent and bivalent stoichiometry to a non-FcRg binding human IgG1. Using
nonhuman primates, we demonstrate that single ultra-low doses of IL-2 fusion proteins induce a prolonged
stateof invivoactivation that increasesTregs foranextendedperiodof timesimilar tomultiple-doseProleukin.
Oneof thecommonpleiotropic effectsofhighdose IL-2 treatment,eosinophilia, iseliminatedatdosesof the IL-
2 fusion proteins that greatly expand Tregs. The long half-lives of the IL-2 fusion proteins facilitated a detailed
characterization of an IL-2 dose response driving Treg expansion that correlates with increasingly sustained,
suprathreshold pSTAT5a induction and subsequent sustained increases in the expression of CD25, FOXP3 and
Ki-67 with retention of Treg-speciﬁc epigenetic signatures at FOXP3 and CTLA4.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).K, pharmacokinetics.
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r Ltd. This is an open access article1. Introduction
CD4þCD25þCD127lo Tregs are crucial for the maintenance of
self-tolerance, they constitutively express FOXP3, a transcription
factor critical for Treg differentiation and function and have sup-
pressive activity associated with expression of CTLA-4, IL-10 and
TGFb [1e4]. The FOXP3 gene is mutated in scurfy mice, which
develop a lethal autoimmune syndrome, and in patients with im-
mune dysregulation polyendocrinopathy, enteropathy, X-chromo-
some linked syndrome (IPEX) resulting in the breakdown of self-
tolerance and the development of autoimmune disease [5].
Genetic susceptibility to several common autoimmune diseases
maps to the IL-2RAgene regionaswell as other genes involved in IL-2
signaling and Treg function [6]. IL-2 plays a major role in the activa-
tionand functionof Tregsandeffector Tcells (Teff): IL-2binds the IL-2under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ing to the activation ofmultiple downstreamsignalingpathways and
altered gene expression. The signal transducer and activator of
transcript (STAT) family of transcription factors are part of one
pathway activated by the Janus-activated kinases and are critical for
theupregulation of FOXP3andCD25 (thea chainof the IL-2 receptor)
in Tregs [7,8]. A deﬁciency in IL-2 production or lack of IL-2 respon-
siveness preferentially leads to a loss of Treg function and an increase
in autoimmunity [9e12]. Tregs constitutively express the trimeric
high afﬁnity receptor for IL-2 (IL-2Rabg) at higher levels than CD4þ
andCD8þ Teff cells, NK cells andeosinophils [13e16]. IL-2 is essential
for Treg survival [17e19] and induction of STAT5a signaling occurs at
lowerdosesof IL-2 inTregs than inTeff [16];henceultra-lowdose IL-2
could stimulate preferential activation and promote the survival of
Tregs in vivo. Proleukin is a recombinant IL-2 traditionally used at
high doses for cancer therapy that has recently been used with
remarkable success at lower doses in graft-versus-host disease
(GVHD) and hepatitis C-induced vasculitis with therapeutic re-
sponses correlating with increased Treg frequencies [20,21]. These
studies led toultra-lowdoseProleukinasprophylaxis inyoungGVHD
patients [22], mechanistic studies and trials testing Proleukin in
healthy volunteers [23] and patients with autoimmune disease
(NCT01840046, NCT02084238, NCT01827735, NCT01988506,
NCT01862120 [24,25]).
Proleukin has a short pharmacokinetic (PK) half-life [26] making
it difﬁcult to maintain low Treg-speciﬁc blood levels since its
frequent, often daily, dosing produces peak blood levels with the
potential to activate non-Tregs such as CD4þ Teff cells, NK cells and
eosinophils. Thus methods to increase the half-life of IL-2, thereby
enabling lower doses of IL-2 to be delivered, are therapeutically
desirable and molecular engineering approaches to increase cyto-
kine half-lives and bioavailability have been recently reviewed, e.g.
a variety of fusion proteins including IgG, antibody complexes and
PEGylation [27]. Several clinical trials for cancer are currently using
IL-2 covalently attached to antibodies that are targeted to mole-
cules enhancing their tumor-speciﬁc distribution, e.g. tenascin C,
ﬁbronectin and DNA/histones [27]. In contrast, here we utilize a
non-targeted IgG molecule as a half-life enhancer to produce IL-2
fusion proteins that can potentially be used in a variety of auto-
immune and inﬂammatory diseases. The use of ﬂexible spacers to
link IL-2 to the Fc region of IgG and the ability to generate IgG
molecules having one or two IL-2 molecules per IgG allowed us to
test the possibility that the avidity of the IL-2 fusion protein could
be increased by providing suitable conformation and spacing of two
IL-2 molecules for engaging two high afﬁnity IL-2 receptors
simultaneously on Tregs. This strategy has the potential to provide
even greater Treg speciﬁcity by further lowering the dose of IL-2
thereby reducing Cmax-associated effects and minimizing occur-
rences of blood levels below the threshold for Treg activation. Ul-
timately such molecules would be expected to have sustained
effects on Tregs and result in improved therapeutic beneﬁts. Here
we test these hypotheses using cynomolgus as a preclinical trans-
lational species. The IL-2 fusion proteins were given at single ultra-
low doses and preferentially activated and increased Tregs up to
two weeks post treatment. Similar responses could be generated
with multiple doses, but not with single doses, of Proleukin. These
attributes enable ultra-low doses of IL-2 with less frequent
administration to maintain long-term enhancement of Tregs.
2. Materials and methods
2.1. Cynomolgus monkeys and NOD.scid Il2ranull mice
Healthy adult male and female cynomolgus monkeys were used
in all tests; they were used in only one test and had never beengiven a human protein. With the exception of epigenetic studies
requiring males, all cynomolgus were randomly assigned to treat-
ment groups without regard to age or gender. All monkeys were in
a colony at Hoffmann-La Roche (Nutley, NJ), were between 4 and 11
years of age and weighed between 4 and 13 kg. All procedures were
performed with adherence to the NIH Guide for the Care and Use of
Laboratory Animals and were approved by the Roche Institutional
Animal Care and Use Committee and the Roche Ethics Committee
for Animal Welfare. Subcutaneous (SQ) injections of 5 ml (1 ml in
each of ﬁve sites) were performed under anesthesia in the lateral
dorsum. Vehicle treatments were 0.5% sterile cynomolgus serum in
PBS. The safety, efﬁcacy and biologic responses to the IL-2 fusion
proteins weremonitored in blood samples taken during the studies
using routine clinical hematology and chemistry analyses with an
Advia Automated Hematology Analyser (Siemens). Lymphocyte
and eosinophil numbers were obtained from the clinical hematol-
ogy complete blood count and in conjunction with ﬂow cytometry
data were used to calculate absolute numbers (per mm3 or per ml)
of speciﬁc cell subsets.
NOD.scid and NOD.scid Il2ranullmicewere obtained from Taconic
Farms (Germantown, NY) and housed under speciﬁc pathogen-free
conditions at Hoffmann-La Roche (Nutley, NJ). The Roche Institu-
tional Animal Care and Use Committee approved all experimental
procedures. The generation of NOD.scid Il2ranull mice was per-
formed under contract at Taconic Farms; brieﬂy, heterozygous
B6.129S4-Il2ratm1Dw/J mice were backcrossed to NOD/MrkTac mice
nine times and then backcrossed twice to NOD.scid mice. Mice
heterozygous for the Il2ranull knockout and homozygous for scid
were intercrossed to generate homozygous NOD.scid Il2ranull mice.
The mice contain at maximum a 3.131 Mb 129 congenic interval
containing the IL2ra knockout, which is deﬁned by the markers
rs27117457 (proximal out), rs27100797 (proximal in), Chr2 12.60
(distal in) and rs13476352 (distal out). A 1449 SNP marker panel
across 19 autosomes and the X chromosome, averaging a genetic
interval of 5 Mbps (1449 marker panel, Taconic) was used to verify
NOD homozygosity throughout the remainder of the genome.
2.2. IL-2
Proleukin® (human recombinant IL-2, Prometheus Laboratories,
San Diego CA) was purchased from a local pharmacy and diluted
with 1.2 ml water for injection with each 1 ml solution containing
1.1 mg (18  106 IU), a new vial of Proleukin was used for each day
of treatment. The IL-2 fusion proteins, IgG-IL-2 and IgG-(IL-2)2,
were prepared at Hoffmann-La Roche (patent WO2014/023752A1).
In brief, the molecules consist of a human IgG1 with V-domain
germline sequences and an engineered short VH CDR3 that has no
known antigen-binding properties on human cells or tissues. Spe-
ciﬁc point mutations in the Fc-portion of the IgG1 (P329G L234A
L235A) rendered it effector silent by abolishing FcRg binding while
leaving normal FcRn function intact. Each IgG1 was engineered to
have one or two wild-type human IL-2 molecules covalently fused
at their N-terminal amino acid to the C-terminus of one or both of
the IgG1 heavy chains (omitting the C-terminal lysine) via a G4S-
peptide linker, i.e. IgG-IL-2 and IgG-(IL-2)2. Knobs-into-holes
technology was used to engineer the monovalent IgG-IL-2
[28,29]. The molecular weights used to calculate pM and pmol/kg
are the following: Proleukin (15,300), IgG-IL-2 (159,088) and IgG-
(IL-2)2 (175,350).
2.3. Surface plasmon resonance
Binding afﬁnities were measured by Biacore surface plasmon
resonance on human, cynomolgus and murine IL-2Ra and IL-2Rbg
on a Biacore T200 (GE Healthcare). Monomeric his-tagged IL2Ra
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fold dilution series (0.41e300 nM) of IgG-IL-2 and IgG-(IL-2)2 was
injected over the chip surface for 90 s and the dissociation was
monitored for 3 min. The surface was regenerated after each in-
jection by washing with 10 mM glycine pH 1.5 for 60 s. Due to the
fast association and dissociation rates, the binding curves were
ﬁtted using a steady state model (BIAevaluation software). To
measure binding to IL2Rbg, a heterodimeric Fc fusion was gener-
ated by applying knobs-into-holes technology [28,29]. The IL2Rb
and g chains were fused to the hole or knob chain of the Fc,
respectively, and co-expressed to obtain the preformed recombi-
nant heterodimer also carrying an avi-tag for site-speciﬁc bio-
tinylation. These biotinylated IL2Rbg heterodimers were
immobilized on streptavidin chips. A 2-fold dilution series of the
cytokine fusion constructs (1.2e300 nM) was injected over the chip
surface for 2 min and the dissociation was monitored for 10 min
(for the two highest concentrations) to observe a measurable decay
of these high-afﬁnity complexes. The surface was regenerated after
each injection bywashingwith 3MMgCl2. The binding curveswere
ﬁtted globally using a 1:1 interaction model (BIAevaluation soft-
ware), despite the bivalent binding of the IgG-(IL-2)2 which is
considered an ‘apparent’ KD. The very slow off-rates result in a low
KD in the pM range that approaches the limit of the instrument.
2.4. In vitro human and cynomolgus blood pSTAT5a
Human blood from healthy adults was collected with informed
consent from the Cambridge BioResource with ethical approval by
the Peterborough and Fenland Local Research Ethics Committee
(05/Q0106/20).
The effects of Proleukin, IgG-IL-2, and IgG-(IL-2)2 on the induction
of pSTAT5a were assessed in human CD4þ Treg subsets, naïve and
memory conventional CD4þ T cells, memory conventional CD8þ T
cells, CD45RAþ CD8þ Tcells, NKTcells and NK cells. IgG-IL-2 and IgG-
(IL-2)2 were assessed in similar cynomolgus cell subsets. All subsets
were characterized in a single tube for each dose of the different IL-2
molecules. Brieﬂy, blood from a healthy human adult donor or cyn-
omolgus monkey was collected into heparinized tubes. Various con-
centrationsof Proleukinor IL-2 fusionproteinswereadded to0.5mlof
blood and incubated at 37 C. After 30 min the blood was lysed and
ﬁxedusingpre-warmed lyse/ﬁxbuffer (BectonDickinsonBiosciences)
for 10minat 37 C,washed 2with PBS containing0.2% BSA followed
by permeabilization with 20 C pre-cooled methanol (Sigma,
Biotech grade) for 20 min on ice. The cells were then extensively
washed 4 with PBS containing 0.2% BSA before FACS staining was
performed using a panel of ﬂuorescent antibodies to distinguish
different lymphocyte andNK cell subpopulations and pSTAT5a status.
The antibodies used for staining human blood cells were CD4-Alexa
Fluor 700 (clone RPA-T4), CD3-PerCP/Cy5.5 (UCHT1), CD45RA-PE/
Cy7 (HI100), CD8-Brilliant Violet 605 (RPA-T8), CD56-Brilliant Violet
421 (HCD56), FOXP3-PE (259D) (all from BioLegend), CD25-APC
(clones M-A251 & 2A3) and pSTAT5a-Alexa Fluor 488 (pY694) (Bec-
ton Dickinson Biosciences). The antibodies used for staining cyn-
omolgus blood cells were FOXP3-Alexa Fluor® 647 (clone 259D,
BioLegend), CD4-V500 (clone L200, BD Biosciences), CD45RA-V450
(clone 5H9, BD Biosciences), CD25-PE (clone 4E3, eBioscience),
pSTAT5a-Alexa Fluor®488 (clone 47, BDBiosciences), and CD3-PerCP-
Cy5.5 (clone SP34-2, BDBiosciences). Sampleswere acquired usingan
LSRFortessa cell analyzer (Becton Dickinson) and data analyzed using
FlowJo software (TreeStar). After gating on lymphocytes and
excluding doublets, human Tregs were deﬁned as CD3þCD4þFOXP3þ
and subdivided as CD3þCD4þCD45RAFOXP3þ (memory Treg) and
CD3þCD4þCD45RAþFOXP3þ (naïve Treg). Conventional CD4þ T cells
weredeﬁnedasCD3þCD4þCD45RAþ (naïve) andCD3þCD4þCD45RA
(memory). CD8þ T cells were deﬁned as CD3þCD8þCD45RA(memory) and CD3þCD8þCD45RAþ (mainly composed of naïve CD8þ
Teff but also containing terminally differentiated CD8þmemory Teff).
Human NKT cells were deﬁned as CD3þCD56þ and NK cells were
deﬁned as CD3CD56þ or CD3CD56bright. Similar to humans, ﬂow
cytometry readily distinguished cynomolgus CD4þFOXP3þ Tregs into
naïve (FOXP3þCD45RAþ) and memory (FOXP3þCD45RA) subsets
with each subset of CD4þCD25þFOXP3þ Tregs expressing high levels
of the high afﬁnity IL-2 receptor CD25. Cynomolgus conventional
CD4þ memory T effector cells can similarly be identiﬁed in blood as
CD4þFOXP3CD45RA cells with approximately 80% of cells being
CD25 and 20% being CD25þ. When memory Teff cells were sub-
divided into CD25 andCD25þ subsets, the response to IL-2wasmore
sensitive in the CD25þ subset than the CD25 subset. CynomolgusNK
cells were identiﬁed as CD3CD8þCD45RAhi. Intracellular pSTAT5a
levels were quantiﬁed in all cell subsets at all doses.
2.5. Ex vivo cynomolgus ﬂow cytometry and pSTAT5a
Similar to human blood, cell surface and intracellular markers
were used to identify regulatory T cell subsets and conventional T
cells in whole blood from cynomolgus monkeys. Blood samples
were collected in heparin before and at various times after treat-
ment with Proleukin or the IL-2 fusion proteins. Blood samples
were lysed and ﬁxed with pre-warmed BD Lyse/Fix buffer (BD
Biosciences). After washing, cells to be stained with the intracel-
lular panel were permeabilized with 1 ml methanol for 30 min on
ice. Samples were washed three times and stained with a panel of
FOXP3-Alexa Fluor® 647 (clone 259D, BioLegend), CD4-V500 (clone
L200, BD Biosciences), CD45RA-V450 (clone 5H9, BD Biosciences),
CD25-PE (clone 4E3, eBioscience), pSTAT5a-Alexa Fluor® 488 (clone
47, BD Biosciences) and Ki-67-PerCP-Cy5.5 (clone B56, BD Bio-
sciences) for 1 h at 4 C. Blood samples were also stained with a
surface panel, which consisted of CD3-Alexa Fluor® 488 (clone
SP34-2, BD Biosciences), CD16-APC (clone 3G8, BD Biosciences),
CD8-V500 (clone SK1, BD Biosciences) and CD122-PE (clone Mik
beta3, BD Biosciences).
2.6. IL-2 and sCD25 immunoassays
The PK properties of IL-2 fusion proteins were evaluated in adult
cynomolgus monkeys injected IV with a short bolus of sterile IgG-
IL-2 or IgG-(IL-2)2 in PBS containing 0.5% cynomolgus serum and
bled at various times after injection, ranging from 30 min to 72 h.
Human IL-2 was assessed in the cynomolgus serum samples using
mouse anti-human IL-2 mAb (clone 5344.111, BD Pharmingen) to
coat 96-well plates in order to immobilize the human IL-2. Human
IL-2 was detected using biotinylated mouse anti-human IL-2 mAb
(clone B33-2, BD Pharmingen). IL-2 binding was quantiﬁed using
Euþþ-conjugated streptavidin. The lower limit of detection using
cynomolgus serum was 0.05 ng/ml of IL-2. Normal cynomolgus
serum had no detectable IL-2 (<0.05 ng/ml). Monoclonal antibody
reagents for human sCD25 known to cross react with cynomolgus
sCD25 were used in a sandwich immunoassay using capture
(MAB623, R&D Systems) and biotinylated detection (BAF223, R&D
Systems) antibodies using Euþþ-conjugated streptavidin to detect
bound sCD25.
2.7. DNA demethylation of FOXP3 and CTLA4
The demethylation signatures of FOXP3 and CTLA4were tested in
sorted CD4þ T cell subsets before and after treatment with IgG-IL-2
(157 pmol/kg, n ¼ 4) and IgG-(IL-2)2 (34 pmol/kg, n ¼ 4). Adult
male cynomolgus whose weights ranged from 9.1 to 10.9 kg were
used in the study. Treatments were administered SQ 3 weeks after
baseline blood collections and post-IL-2 treatment bloods were
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30ml of bloodwere sorted using a FACSAria (Becton Dickinson) into
relevant CD4þ subsets including Tregs (CD4þCD25þCD127low),
memory T effectors (CD4þCD45RA), naïve T effectors (CD4þ
CD45RAþ), and CD4þCD25CD127 cells. In post-treatment blood
we were able to sort additional subsets of Tregs that were CD25hi
(CD4þCD25hiCD127low) or CD25int. In normal blood CD25hi cells
represent less than 1% of the total Tregs were there were insufﬁcient
numbers to sort.
Sorted cell subsets were frozen in aliquots of 100,000 cells and
stored as dry pellets at 80 C to allow processing of all samples
together. Cell pellets obtained from sorting were thawed and DNA
was extracted and bisulﬁte treated in a single step using Epitect Fast
Lyse All kit (Qiagen). 5 ng (in 2 ml) of bisulﬁte DNA was used in a
20 ml ﬁrst round duplex PCR containing 10 ml Multiplex PCR kit
(Qiagen), 6 ml water, 0.5 ml FOXP3 forward primer tgtaaaacgacggcc
agtTTTAGAAGTTGTATGGGGGATGTT, 0.5 ml FOXP3 reverse primer
caggaaacagctatgaccAAAATATCTACCCTCTTCTCTTCCTC, 0.5 ml CTLA-4
forward primer tgtaaaacgacggccagtGGGTTTGGTTATGAAGGAGTAT
GA and 0.5 ml CTLA-4 reverse primer caggaaacagctatgaccTTC
ACTTAATTTCCACTAAAAATACCC. First round PCR cycling was 95 C
for 15 min followed by 20 cycles of 95 C for 30 s, 60 C for 90 s and
72 C for 60 s, followed by 10min at 72 C. PCR product was puriﬁed
using AMPure XP beads (Becton Coulter) according to manufac-
turer's instructions, and eluted in 20 ml of water. A second round of
PCR was performed that added a unique index sequence to the
beginning of each sample, through a 15 ml PCR containing 7.5 ml of
Multiplex PCR kit (Qiagen), 6.5 ml of ﬁrst round PCR product and 1 ml
of index primer. Second round PCR cycling conditionswere 95 C for
15min followed by 7 cycles of 95 C for 30 s, 54 C for 90 s and 72 C
for 60 s, followed by 5 min at 72 C. The PCR products were puriﬁed
using AMPure XP beads and eluted in 15 ml of water, and 4 ml was
used to quantify the amount of PCR product using a Shimadzu
Multina. Equal molar amounts of each sample were pooled to make
the sequencing library which was quantiﬁed using a Kapa Illumina
library quantiﬁcation kit. The library was sequenced using an Illu-
mina MiSeq with v3 reagents and 2 300 bp paired-end reads. The
sequence data were de-multiplexed using a bespoke python script
and the Cutadapt programwas used to remove sequences generated
from sequencing adaptors. Forward and reverse reads weremerged
using FLASH and the sequence of each methylation site was
extracted.
2.8. Data analysis
Prism 6 (GraphPad Software, Inc.) was used to calculate area
under the curve (AUC); each set of data provided individual base-
line Y-values and by deﬁnition, all peaks were above baseline.
Unless noted, all data are shown as the mean ± SEM and p values
calculated with Prism 6.
3. Results
3.1. Increased avidity enhances in vitro biologic activities
Human and cynomolgus whole blood assays measuring cell-
speciﬁc increases in pSTAT5a and Biacore surface plasmon reso-
nance assessing binding to IL-2 receptor components were used to
characterize the cell activation potencies and binding afﬁnities of
IgG-IL-2 and IgG-(IL-2)2. For reference, the IL-2 fusion proteins are
depicted (Supplemental Fig. 1) and the ﬂow cytometry gating used
to identify speciﬁc cynomolgus blood cell subsets is shown
(Supplemental Fig. 2).
In humanwhole blood the induction of pSTAT5a by monovalent
forms of IL-2, i.e. Proleukin and IgG-IL-2, was comparable across avariety of cell types (Fig. 1A, E, Supplemental Fig. 1C). Human
memory and naïve Treg dose responses with IgG-IL-2 produced
ED50s averaging 1.8 and 2.2 pM and Proleukin ED50s averaged 1.5
and 2.0 pM, respectively. Cynomolgus memory and naïve Treg dose
responses with IgG-IL-2 in whole blood generated similar ED50s to
human Tregs, 1.0 and 0.5 pM, respectively (Fig. 1C, E). In contrast,
IgG-(IL-2)2 dose responses and ED50 values improved beyond the 2-
fold increase in stoichiometry indicating that the structure of the
IgG-(IL-2)2 fusion protein enables an increased avidity for the IL-2
receptor. Human Treg ED50s for IgG-(IL-2)2 averaged 0.3 pM, a 7-
fold increase in potency compared to IgG-IL-2 and cynomolgus
Treg ED50s averaged 0.1 pM, a similar 7-fold increase in potency as
human Tregs (Fig. 1B, D, E).
Compared to Tregs, human memory CD4þ Teff required 10-fold
higher concentrations of all three IL-2 molecules to reach their
ED50s for IL-2 stimulated pSTAT5 responses (Fig. 1A, B, E,
Supplemental Fig. 1C). Although >80% of human CD4þ memory
cells are CD25þ, we previously observed reduced pSTAT5 responses
to IL-2 in the small proportion of memory cells lacking or having
very low CD25 expression [16]. Therefore we analyzed CD25 levels
on cynomolgus memory CD4þ Teff and found that on average only
~20% are CD25þ (Supplemental Fig. 2E) initiating an assessment of
pSTAT5a separately in CD25þ and CD25CD4þ memory Teff cells.
Consistent with their expression of CD25, cynomolgus CD25þ
memory Teff cells responded to lower concentrations of IL-2 and
attained a higher level of pSTAT5a compared to the CD25CD4þ
memory population (Fig. 1C, D). The ED50s for IgG-IL-2 and IgG-(IL-
2)2 in cynomolgus CD25þ memory Teff cells were similar to those
seen on human memory Teff cells and approximately 10-fold more
of the fusion proteins were required to stimulate a half-maximal
pSTAT5 response compared to Tregs (Fig. 1E).
In one additional population of cells, a subpopulation of human
NK cells termed CD56bright, IL-2 molecules at relatively low con-
centrations (7e16 pM) induced pSTAT5a (Fig. 1A, B, E,
Supplemental Fig. 1C). We did not observe a similar subpopulation
of NK cells in cynomolgus that was sensitive to low concentrations
of IL-2. The bulk NK population in both human and cynomolgus
required 100e1000 pM IL-2 to induce detectable levels of pSTAT5a,
as did all other cell types examined (Fig. 1AeD).
The binding afﬁnities of human IgG-IL-2 and IgG-(IL-2)2 for
human, cynomolgus and murine IL-2Ra and IL-2Rbg were deter-
mined by Biacore surface plasmon resonance (Supplemental Figs. 3
and 4). For all three species of IL-2Ra, the binding of IgG-IL-2 and
IgG-(IL-2)2 was relatively low afﬁnity, in nM ranges (Supplemental
Fig. 3). By contrast, binding to the IL-2Rbg heterodimer was of very
high afﬁnity, in pM ranges. With IgG-IL-2 the KD for human, cyn-
omolgus and mouse IL-2Rbgwere 40, 180 and 750 pM, respectively
(Fig. 1F and Supplemental Fig. 3). With IgG-(IL-2)2, substantial in-
creases in binding afﬁnity were seen to IL-2Rbgwith KD values of 3,
40 and 40 pM for human, cynomolgus and murine receptors,
respectively. Changing the stoichiometry to IgG-(IL-2)2 increased
its avidity and produced a 13-fold increase in binding afﬁnity to
human IL-2Rbg, from 40 pM to 3 pM.
3.2. Increased Treg frequency and number in cynomolgus after
treatment with IL-2 fusion proteins
In our colony (n ¼ 51) cynomolgus Tregs averaged 57/mm3
blood (median of 56.5/mm3, mean of 57.3/mm3 ± SD 20.8, ranging
from a low of 17/mm3 to a high of 96/mm3) (Supplemental Fig. 5A)
and averaged 4.0% of the total CD4þ Tcells (median of 4.0%, mean of
4.1% ± SD 1.0, ranging from a low of 2.0 to a high of 6.2)
(Supplemental Fig. 5B). Given these ranges in the normal distri-
butions in both Tregs/mm3 and Tregs as % of CD4þ T cells, it was
interesting to ﬁnd there was no correlation from animal-to-animal
Fig. 1. Characterization of IgG-IL-2 and IgG-(IL-2)2. (AeD) IgG-IL-2 and IgG-(IL-2)2 were tested for their ability to stimulate pSTAT5a in human whole blood and in cynomolgus
whole blood; representative human and cynomolgus samples are shown. (E) ED50 values for pSTAT5a induction were determined for IgG-IL-2, IgG-(IL-2)2 and Proleukin (see
Supplemental Fig. 1C for the titration of Proleukin); human blood IgG-IL-2 (n ¼ 4 donors, mean ± SD); IgG-(IL-2)2 (n ¼ 11 donors, mean ± SD); Proleukin (n ¼ 3 donors, mean ± SD);
cyno blood IgG-IL-2 (n ¼ 1), IgG-(IL-2)2 (n ¼ 2, both determinations shown); ND, not determined. (F) Association and dissociation rate constants and binding afﬁnities of IgG-IL-2
and IgG-(IL-2)2 to IL-2Rbg were determined by Biacore surface plasmon resonance and kinetic analysis.
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% of CD4þ Tcells (Supplemental Fig. 5C). Because of this, we present
changes in Tregs using both metrics.
To assess the ability of Proleukin, IgG-IL-2 and IgG-(IL-2)2 to
expand cynomolgus Tregs in vivo, single SQ injections were given
and cell subsets in blood monitored over time; all of the results are
presented as pmol/kg to facilitate comparisons between the
different IL-2 molecules. Treatment-related changes in Tregs were
dose-dependent and changes from each animal's individual base-
line are shown as the increase in the number of Tregs/mm3 blood
(Fig. 2A) and as the increase in Tregs as the % of CD4þ Tcells (Fig. 2B)
with “0” equal to no treatment-related change. Following 13, 38
and 157 pmol/kg of IgG-IL-2, cynomolgus Tregs increased both in
number: 50/mm3, 62/mm3 and 193/mm3 and as the % of CD4þ Tcells: 2.1%, 4.2% and 7.7%. After 4, 11 and 34 pmol/kg of IgG-(IL-2)2,
cynomolgus Treg increases were 18/mm3, 44/mm3, and 120/mm3
and 0.8%, 1.6% and 8.1% of CD4þ T cells. Proleukin-induced changes
in Tregs with 40, 120 and 400 pmol/kg were 1/mm3, 22/mm3 and
15/mm3 and 1%, 0.8% and 1.3% of CD4þ T cells.
After IgG-IL-2 and IgG-(IL-2)2 dosing, increases in cynomolgus
Tregs peaked between 4 and 7 days with Tregs still above baseline
at 14 days, 82% and 69% respectively (Fig. 2C). To quantify the
changes in Tregs in Fig. 2C we measured the area under the curve
(AUC) for Proleukin and the IL-2 fusion proteins (Fig. 2D). The AUCs
for Tregs/mm3 were similar between the IL-2 fusion proteins and
both were strikingly different from Proleukin: IgG-(IL-2)2 yielded
an AUC that was 80% of that induced by IgG-IL-2, while Proleukin
generated an AUC that was 6% of IgG-IL-2 and 8% of IgG-(IL-2)2. As a
Fig. 2. Increases in Tregs after single dose in vivo IL-2 treatments. (A) Dose-dependent changes in Tregs are shown as maximal increases in Tregs/mm3 blood above individual
baselines and (B) as % of total CD4þ T cells above individual baselines; baseline Tregs averaged 57/mm3 and 4% of total CD4þ T cells. (C) Changes in Tregs/mm3 over two weeks are
shown for Proleukin (400 pmol/kg, n ¼ 3), IgG-IL-2 (157 pmol/kg, n ¼ 6) and IgG-(IL-2)2 (34 pmol/kg, n ¼ 5). (D) AUC results for the time-dependent responses in Tregs/mm3 are
compared. (E) Dose-dependent increases in memory Tregs/mm3 are shown as fold-changes and in (F) as % of total CD4þ T cells; baseline memory Tregs averaged 2%. (G) Serum
levels of IL-2 are shown after SQ dosing of IgG-IL-2 (226 pmol/kg, n ¼ 2) and IgG-(IL-2)2 (34 pmol/kg, n ¼ 2). (H) Dose-normalized serum levels of IgG-IL-2 (600 pmol/kg) and IgG-
(IL-2)2 (1700 pmol/kg) after IV dosing are shown from NOD.scid Il2ranull mice (open symbols) and NOD.scid mice (shaded symbols) (n ¼ 3); for mice dosed with Proleukin
(6500 pmol/kg), results from both strains were identical and the pooled results are shown (n ¼ 6).
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omolgus Tregs/mm3 induced by the low-dose IL-2 fusion proteins
(Fig. 2C) are equivalent to the Tregs/mm3 in human GVHD patients
treated daily with 1  106 IU/m2 Proleukin [20]. Overall, the dose-
dependent increases of cynomolgus Tregs/mm3 blood, the
increased Treg % in CD4þ T cells and the AUCs of the Treg responses
over two weeks demonstrate the effectiveness of the IL-2 fusion
proteins. These observations support the hypothesis that extending
the in vivo half-life of IL-2 causes long-lasting induction of Tregs at
ultra-low doses.
We monitored for changes in cynomolgus CD4þ memory Teff
cells and hence potential adverse effects of therapy with a long-
lived IL-2 molecule. Absolute numbers of CD4þ memory Teffs/ml
of blood showed no treatment-related increases following the
highest doses of Proleukin, IgG-IL-2 and IgG-(IL-2)2 (Supplemental
Fig. 1D). There were no detectable increases seen in
CD3CD8þCD122þ NK cells and CD3þCD8þ T cells. Interestingly a
transient drop in lymphocytes and NK cells was seen after all but
the lowest doses of Proleukin and IL-2 fusion proteins
(Supplemental Fig. 6A, B). The drop in lymphocyte and NK cellsoccurredwithin one day of dosing and returned to normal 4e7 days
later.
Memory Tregs comprise a majority of cynomolgus Tregs
(Supplemental Fig. 5B, D) and both IgG-IL-2 and IgG-(IL-2)2 stim-
ulated 5-fold increases in memory Tregs/mm3 blood (Fig. 2E) and
increased their frequency from 2% to 6e7% of CD4þ T cells at the
highest doses tested (Fig. 2F); in comparison Proleukin increased
their frequency from 2.2% to 3.2%. Increases of naïve Tregs while
less pronounced than memory Tregs were seen for all treatments
especially at higher doses (Supplemental Fig. 7).
The PK properties of IgG-IL-2 and IgG-(IL-2)2 in cynomolgus
were compared to the known short duration of Proleukin (IV t1/2
13 min, SQ t1/2 3.3 h) [30]. IgG-IL-2 and IgG-(IL-2)2 had IV t1/2 of
8 h and SQ t1/2 of 14 h (Fig. 2G). While prolonged compared to
Proleukin, the half-lives were less than the expected 14 day t1/2 of
human IgG1 in cynomolgus [31] suggesting IL-2 receptor-medi-
ated clearance. We tested this by measuring the PK of IgG-IL-2,
IgG-(IL-2)2 and Proleukin in CD25 knockout (Il2ranull) versus
CD25-replete mice (Fig. 2H). Since CD25 knockout mice develop
lethal autoimmunity and massive expansion of T cells [32], we
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immune system by virtue of having a scid mutation, i.e. NOD.scid
IL2ranull. Clearance of IgG-IL-2 and IgG-(IL-2)2 in CD25-replete
NOD.scid mice was more rapid and increased 5-fold compared to
NOD.scid IL2ranull mice consistent with CD25 expression and IL-2
uptake by cells outside the adaptive immune system, including
endothelial cells, dendritic cells and NK cells [33,34]. With its
rapid clearance by the kidneys, levels of Proleukin were below the
limit of detection after 2.5 h and no difference was seen in Pro-
leukin clearance when comparing sera from NOD.scid and
NOD.scid IL2ranull mice.
3.3. STAT5a phosphorylation is prolonged in cynomolgus with IL-2
fusion proteins
IL-2 stimulation of pSTAT5a is a sensitive proximal biomarker of
Treg activation. To assess the magnitude and duration of activation
after in vivo treatment, we monitored pSTAT5a over time by
sequentially collecting blood after treatment without further
ex vivo stimulation. Clear kinetic differences in memory and naïve
Treg pSTAT5a responses were seen between the highest doses of
IgG-(IL-2)2 (34 pmol/kg) and Proleukin (400 pmol/kg): maximal
Treg pSTAT5a levels were maintained for 4 days with IgG-(IL-2)2Fig. 3. Long-lived pSTAT5a activation after in vivo IL-2 treatment. As a measure of IL-2 trea
further stimulation. Time courses are shown for (A) IgG-(IL-2)2 (34 pmol/kg) and (B) Proleu
(34 pmol/kg) and Proleukin (400 pmol/kg) time courses. (D) The dose-dependent increases
MFIs were 170 and 175 as indicated. (F) The IgG-(IL-2)2 dose-dependent (pmol/kg) time cou
blood. (H) The dose-dependent responses to IgG-(IL-2)2 are expressed as the AUCs for pSTAT
IgG-IL-2 (all doses, n ¼ 6); IgG-(IL-2)2 (11 and 34 pmol/kg, n ¼ 5; 4 pmol/kg, n ¼ 3); and P(Fig. 3A) and for one day with Proleukin (Fig. 3B). AUC analysis
quantiﬁed Proleukin-induced naïve and memory Treg responses at
25% of the IgG-(IL-2)2 responses (Fig. 3C). Both IgG-(IL-2)2 and
Proleukin stimulated pSTAT5a in CD4þmemory Teff cells but not to
near the extent of Tregs and is reﬂected by the lower maximum
MFIs and AUCs. CD25CD4þ naïve Teff cells were unresponsive
using the criteria of pSTAT5a induction and had no quantiﬁable
AUC.
Proleukin, IgG-IL-2 and IgG-(IL-2)2 all stimulated dose-
dependent pSTAT5a responses in memory and naïve Tregs
(Fig. 3D, E). Proleukin stimulated maximal pSTAT5a responses at
400 pmol/kg, had limited effects at 120 pmol/kg and had no effect
at 40 pmol/kg. In contrast, IgG-IL-2 and IgG-(IL-2)2 stimulated
pSTAT5a at the lowest administered doses, 4 and 13 pmol/kg,
respectively and both IgG-IL-2 and IgG-(IL-2)2 showed dose-
dependent superiority at stimulating maximal and sustained
in vivo pSTAT5a responses.
We next compared IgG-(IL-2)2 dose and time-dependent
pSTAT5a induction in Tregs (Fig. 3F) with their in vivo expansion
(Fig. 3G). The extent of Treg expansion was dependent and
correlated with a pSTAT5a response that was sustained at a suf-
ﬁcient level for an extended signaling period. The highest dose of
IgG-(IL-2)2 (34 pmol/kg) stimulated Treg pSTAT5a that wastment, pSTAT5a was monitored over one week and whole blood assayed daily without
kin (400 pmol/kg). (C) The AUC of pSTAT5a responses are compared for the IgG-(IL-2)2
in pSTAT5a are shown for memory Tregs and (E) for naïve Tregs; unstimulated pSTAT5a
rses for pSTAT5a induction in Tregs and (G) the corresponding increases in Tregs/mm3
5a induction and the corresponding AUCs for increases in Tregs/mm3. Group sizes were:
roleukin (40 and 400 pmol/kg, n ¼ 3; 120 pmol/kg, n ¼ 4).
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increased from 38 to 162/mm3 and were still elevated on days 11
(126%) and 14 (76%). The lower doses of IgG-(IL-2)2 (11 and
4 pmol/kg) stimulated less pSTAT5a and smaller increases in the
number of Tregs/mm3. These dose and time-dependent effects
were quantiﬁed as AUCs and then compared (Fig. 3H). A clear
correlation and dose relationship was seen between the AUCs for
pSTAT5 signaling and the AUCs for increased Tregs/mm3. The re-
sults ranged from a threshold of effects at the lowest dose to
maximal changes at the highest dose.Fig. 4. Increases in CD25 as a biomarker of IL-2-induced in vivo activation. Cell surface CD25
of IgG-(IL-2)2 (4 pmol/kg) and Proleukin (40 pmol/kg) and (C, D) after the highest doses o
stimulation are shown for low and high-dose IgG-(IL-2)2 and Proleukin on naïve and mem
Proleukin are shown for memory Tregs and naïve Tregs; unstimulated CD25 MFIs were 2600
IgG-(IL-2)2. Group sizes were: IgG-IL-2 (all doses, n ¼ 6); IgG-(IL-2)2 (11 and 34 pmol/kg, n ¼3.4. CD25, FOXP3, Ki-67 and soluble CD25 are biomarkers of IL-2
treatment in cynomolgus
We measured dose and time-dependent increases in CD25
expression on Tregs and found upregulation of CD25 was more
long-lived than pSTAT5a. At ultra-low doses of IgG-(IL-2)2, maximal
CD25 responses were maintained in memory (Fig. 4A, C) and naïve
Tregs (Fig. 4B, D) out to 4 days and were still above background at
11 days. Proleukin stimulated CD25 responses at 24 h in memory
(Fig. 4A, C) and naïve Tregs (Fig. 4B, D) and returned to normal at 7on memory Tregs and Teff and naïve Tregs are shown following (A, B) the lowest doses
f IgG-(IL-2)2 (34 pmol/kg) and Proleukin (400 pmol/kg). (E) The AUC results for CD25
ory Tregs. (F, G) The dose-dependent increases in CD25 for IgG-IL-2, IgG-(IL-2)2 and
and 3980 as indicated. (H) Soluble CD25 was measured in serum from IV studies with
5; 4 pmol/kg, n ¼ 3); and Proleukin (40 and 400 pmol/kg, n ¼ 3; 120 pmol/kg, n ¼ 4).
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them to each other (Fig. 4E); this illustrates that increasing the half-
life of IL-2 via the fusion proteins had amajor impact on the breadth
and depth of in vivo activation. No changes in the expression of
CD25 were seen in CD25þCD4þ memory Teff cells in any experi-
ment (Fig. 4A, C). IL-2 treatment in man is known to increase levels
of circulating sCD25 [35] and we observed a dose-dependent in-
crease of sCD25 in cynomolgus after receiving IgG-(IL-2)2 (Fig. 4H).
Expression of FOXP3 is a hallmark of Tregs and was upregulated
in cynomolgus memory and naïve Tregs as a consequence of in vivo
activation and as we found for CD25, its expression was longer-
lived than pSTAT5a responses. The lowest doses of Proleukin and
IgG-(IL-2)2 stimulated small increases in FOXP3 that quickly
returned to normal (not shown)while higher doses induced greater
and more sustained effects (Fig. 5A, B). Similar to CD25, IgG-(IL-2)2
(34 pmol/kg) stimulated Treg FOXP3 expression for 4e5 days and
remained above baseline at 11 days. Proleukin responses
(400 pmol/kg) peaked at 24 h and returned to normal by days 4e7.Fig. 5. Intracellular FOXP3 as a biomarker of IL-2-induced in vivo activation. (A, B) The tim
(34 pmol/kg) and Proleukin (400 pmol/kg) in memory Tregs and naïve Tregs. (C) The AUC re
in memory and naïve Tregs. (D, E) The dose-dependent increases in FOXP3 for IgG-IL-2, IgG-(
MFIs were 1200 and 800 as indicated. Group sizes were: IgG-IL-2 (all doses, n ¼ 6); IgG-(IL-
n ¼ 3; 120 pmol/kg, n ¼ 4).As with CD25, we quantiﬁed AUCs for the Treg FOXP3 responses
and compared them to each other (Fig. 5C), again showing the
major impact on in vivo activation the fusion proteins generated in
memory and naïve Tregs, i.e. a 6-fold larger AUC at a 10-fold lower
dose compared to Proleukin. There was no induction of FOXP3 in
CD4þ memory Teff cells (not shown).
Ki-67 is an intracellular marker of entry into cell cycle and
proliferation. Untreated memory Tregs had the highest basal level
of proliferation, averaging 33% Ki-67þ, while naïve Tregs and CD4þ
memory Teff averaged 4% and 8% cells in cycle, respectively. After
ultra-low dose IgG-(IL-2)2 treatment the number of memory Tregs,
naïve Tregs and memory Teff cells in cell cycle increased 14%, 12%
and 9% (Fig. 6A) and after Proleukin 8%, 4% and 4% (Fig. 6B).
Following the highest dose of IgG-(IL-2)2, memory Tregs, naïve
Tregs and memory Teff cells in cell cycle increased by 36%, 47% and
14% (Fig. 6C) and after Proleukin by 16%, 6% and 3% (Fig. 6D).
Maximal increases in Ki-67þ cells peaked 5 days after IgG-(IL-2)2
and 3 days after Proleukin. Treatment-related increases in Ki-67þe-dependent ability to stimulate FOXP3 is shown for the highest doses of IgG-(IL-2)2
sults for FOXP3 stimulation are shown for low and high-dose IgG-(IL-2)2 and Proleukin
IL-2)2 and Proleukin are shown for memory Tregs and naïve Tregs; unstimulated FOXP3
2)2 (11 and 34 pmol/kg, n ¼ 5; 4 pmol/kg, n ¼ 3); and Proleukin (40 and 400 pmol/kg,
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dependent effects of IgG-IL-2, IgG-(IL-2)2 and Proleukin (Fig. 6E,
F) with IgG-(IL-2)2 having a >10-fold advantage in potency.
3.5. FOXP3 and CTLA4 remain demethylated in cynomolgus Tregs
after IL-2 induced in vivo expansion
Constitutive expression of FOXP3 in mouse Tregs is associated
with functional suppression and relies on demethylation of CpG
DNA methylation sites in the Treg-speciﬁc demethylated region
(TSDR) within intron 1 of Foxp3 [36]. An orthologous region in
human FOXP3 is also speciﬁcally demethylated in human Tregs.
Human Teff cells activated and differentiated in vitro express
FOXP3 protein but unlike Tregs, the TSDR remains methylated
[37,38]. Similarly, mouse Tregs are preferentially demethylated
within a region of Ctla4 exon 2 compared to conventional T cells
[39].Fig. 6. Intracellular Ki-67 as a marker for induction into cell cycle and proliferation. The abil
in vivo activation. (A, C) The ability to stimulate Ki-67 is shown for low and high doses of IgG
increases in Ki-67 for IgG-IL-2, IgG-(IL-2)2 and Proleukin are shown for memory Tregs and
respectively, as indicated. Group sizes were: IgG-IL-2 (all doses, n ¼ 6); IgG-(IL-2)2 (11 an
120 pmol/kg, n ¼ 4).To determine if cynomolgus Tregs retained epigenetic signa-
tures consistent with being functional Tregs after in vivo expansion,
we developed NGS-based sequencing of the regions in FOXP3 and
CTLA4 homologous to those deﬁned in mice and humans that are
preferentially demethylated in Tregs [39,40]. We assessed methyl-
ation in sorted cynomolgus Treg and non-Treg CD4þ T cell subsets
before and after dosing with IgG-IL-2 and IgG-(IL-2)2 (Fig. 7). The
doses chosen to expand Tregs were based on the previous tests
where IgG-(IL-2)2 (34 pmol/kg) increased Tregs from 4% to 11% and
IgG-IL-2 (157 pmol/kg) increased Tregs from 4% to 12%. Using these
doses again, IgG-IL-2 and IgG-(IL-2)2 each raised total Tregs from 4%
of total CD4þ cells to 11.2% (Fig. 7A). Only a small number of
memory Tregs (~300 cells/ml of blood) expressed high levels of
CD25 (Supplemental Fig. 7A, B) and are considered “activated”
Tregs [40]. While blood volume limitations prevented assessing
this rare subset before treatment, the activated Treg population
greatly expanded after treatment (Supplemental Fig. 7C, D) andity to stimulate proliferation was quantiﬁed using Ki-67 as a biomarker of IL-2-induced
-(IL-2)2 and (B, D) compared to low and high doses of Proleukin. (E, F) Dose-dependent
naïve Tregs; the unstimulated % Ki-67þ memory and naïve Tregs were 33% and 4%,
d 34 pmol/kg, n ¼ 5; 4 pmol/kg, n ¼ 3); and Proleukin (40 and 400 pmol/kg, n ¼ 3;
Fig. 7. DNA demethylation before and after IL-2 treatment. The epigenetic signatures of FOXP3 and CTLA4 were measured before and after IgG-IL-2 (157 pmol/kg, n ¼ 4, C1eC4) or
IgG-(IL-2)2 (34 pmol/kg, n ¼ 4, C5eC8) induced in vivo expansion. (A, B) Baseline and post-treatment induction of Tregs and CD25hi Tregs are shown. The methylation status of
sorted naïve and memory Teff and total, CD25inter and CD25hi Tregs (Supplemental Fig. 8) was assessed with Next Generation Sequencing; methylated cytosines are read as C and
demethylated cytosines as T. (C, D) To visualize the demethylation results, the proportion of cytosines methylated versus demethylated at each of the relevant CpG sites is shown for
FOXP3 and CTLA4. (E, F) These demethylation results are graphically shown for FOXP3 and CTLA4.
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Fig. 7F, G). The CD25hi Tregs increased 30-fold from 0.5 to 0.7% of
total Tregs to 20% and 16% of total Tregs after IgG-IL-2 and IgG-(IL-
2)2, respectively (Fig. 7B). A human memory Treg subset with in-
termediate levels of CD25 (CD25int) has been shown to contain a
high proportion of cells (60%) lacking the epigenetic signature of
Tregs [40]. Following expansion there were a sufﬁcient number of
CD25int Tregs to isolate for analysis (Supplemental Fig. 7E).
Bisulﬁte sequencing of DNA from cells sorted from pre-dose
blood conﬁrmed the Treg-speciﬁcity of the cynomolgus FOXP3
TSDR (Fig. 7C, E): total Tregs for the eight cynomolgus in the test
were on average 85% demethylatedwhereasmemory and naïve Teff
(Supplemental Fig. 7HeJ) were both <1% demethylated. Although
CTLA4 demethylation in exon 2 was not completely speciﬁc for
Tregs, as reported for mice [39], Treg-biased demethylation was
observed prior to expansion with Tregs > memory Teff[ naïve
Teff (Fig. 7D, F). Notably, after undergoing signiﬁcant in vivo
expansion, Tregs retained the identical FOXP3 and CTLA4 methyl-
ation patterns compared to pre-dose Tregs indicating that they
retained their functional signatures (Fig. 7C, D). Importantly, total
CD25þCD127lo Tregs as well as CD25hi activated Tregs and CD25int
Tregs retained a Treg demethylation pattern indicating that the
Treg expansion following IL-2 dosing was not attributable to highly
activated effector CD4þ T cells.
3.6. Multiple dosing with Proleukin expands cynomolgus Tregs
In this study, single doses of Proleukin equivalent to 1.2106 IU/
m2 in humans (Supplemental Fig. 1D) stimulated modest 30% in-
creases in Tregs (Fig. 2). In contrast, Tregs in type 1 diabetics
increased 100e200% (2e3-fold) following 4.5  106 IU Proleukin/
per person three times per week for four weeks [35,41]. Using body
surface area for dose translation across species [42], 4.5  106 IU/
person converts to an equivalent cynomolgus dose of 200,000 IU/
kg (800 pmol/kg); hence we dosed ﬁve cynomolgus with Proleukin
at 800 pmol/kg three times per week for 15 days for a total of seven
doses. With this multi-dose regimen, cynomolgus Tregs increased
from 81 to 197/mm3 (2.4-fold, 143%) (Fig. 8A) and memory and
naïve Tregs increased 2.6-fold and 1.9-fold, respectively (Fig. 8B),
results equal to T1D patients receiving dose equivalent treatment
[35]. The number of Tregs appeared to decline with continued
dosing suggesting enhanced migration or exhaustion. Despite
continued dosing, pSTAT5a was maximal for only 1e3 days and
declined thereafter (Fig. 8C). Compared to single-dose Proleukin
(Fig. 6D), multiple-dosing did not increase further the number of
Ki-67þ Tregs in cell cycle but did maintain their numbers for the
duration of dosing (Fig. 8D). Treg CD25 levels increased on days 1e3
followed by a decline in expression (not shown). As in other ex-
periments, there was a transient lymphopenia (Supplemental
Fig. 6A) and there were no increases in memory Teff (Fig. 8A),
naïve Teff (not shown) or NK cells (Supplemental Fig. 6B).
3.7. IL-2-induced eosinophilia is dose dependent
In humans, repeated doses of 1  106 to 4.5  106 IU Proleukin
induce a signiﬁcant increase in eosinophils [20,35]. In this study,
cynomolgus eosinophils were measured in normal pre-IL-2 treat-
ment bloods (n ¼ 44) with a median of 0.23  106/ml, a mean of
0.28  106/ml ± SD 0.16, with a low of 0.07  106/ml and high of
0.86  106/ml (Fig. 8E). Using these colony reference values we
considered that numbers above 1  106/ml qualiﬁed as eosino-
philia. After applying this criterion, all cynomolgus given multiple-
dose Proleukin (800 pmol/kg, 7 doses) developed eosinophilia. IgG-
IL-2 had a clear dose-dependent ability to increase eosinophils
above 1  106/ml while no single doses of IgG-(IL-2)2 or Proleukininduced eosinophilia. The increase in eosinophils induced by
multiple-dose Proleukin continued throughout the dosing regimen
while that of IgG-IL-2 peaked at day 7 and declined (Fig. 8F).
These results in cynomolgus demonstrate that a reduction of the
IL-2 dose facilitated by an extended half-life and increased avidity
for the IL-2R provided a greater degree of cell speciﬁcity in favor of
Tregs. To illustrate this in light of the ability to induce eosinophilia
(Fig. 8E), we compiled the results for single and multiple-dose
Proleukin and single-dose IgG-IL-2 and IgG-(IL-2)2 for their abil-
ity to increase Tregs (Fig. 8G). Single-dose Proleukin had little effect
on Tregs and no effect on eosinophils while multiple-dose Proleu-
kin (7) substantially increased Tregs and eosinophils in 100% of
the animals. IgG-IL-2 at its highest dose stimulated similar in-
creases in Tregs as multi-dose Proleukin but only induced eosino-
philia in 50% of the animals. The advantage of a prolonged half-life
and increase in avidity was clearest when IgG-(IL-2)2 at an ultra-
low dose stimulated an increase in Tregs similar to multi-dose
Proleukin and IgG-IL-2 in 100% of the animals but had no effect
on eosinophils.
4. Discussion
Over the last 20 years we have progressed from discovering that
IL-2 and IL-2RA are genetically associated with autoimmune dia-
betes and the functional state of Tregs to seeing dramatic clinical
success with IL-2 in chronic GVHD. The central role of IL-2 in the
maintenance of self-tolerance and Treg function is now immuno-
logical canon and many attempts are being made to harness Tregs
to combat a variety of autoimmune and inﬂammatory diseases. The
recent clinical successes with Proleukin are noteworthy since
pharmacologically it is a drug with limitations: its short half-life
requires daily or every other day injection and the doses used to
date stimulate CD4þ T effector cells, NK cells and eosinophils in
addition to Tregs. Our goal was to develop and characterize IL-2
molecules with improved pharmacologic proﬁles that could be
delivered less frequently and at lower doses than Proleukin and
selectively expand Tregs that maintained their epigenetic proﬁles
at FOXP3 and CTLA4.
Increasing the in vivo half-life of IL-2 by fusion to IgG1, i.e. IgG-IL-
2, results in a molecule that can induce a 4-fold increase in Tregs
after a single dose in cynomolgus, a response that multiple-dose,
but no single dose, of Proleukin can achieve. Increasing the stoi-
chiometry and hence the avidity, i.e. IgG-(IL-2)2, increases the po-
tency and stimulates a similar increase in Tregs albeit at a 5-fold
lower dose than IgG-IL-2. A detailed characterization of the in vivo
dose responses for Proleukin and IgG-(IL-2)2 highlights that the
magnitude and duration of Treg expansion, deﬁned by its AUC,
correlates with the magnitude and duration of pSTAT5a upregula-
tion, also deﬁned by its AUC. Single doses of Proleukin that increase
pSTAT5a for one day have a minimal AUC and as a consequence
little impact on Treg numbers; whereas single dose IgG-IL-2 and
IgG-(IL-2)2 or multiple-dose Proleukin stimulate pSTAT5a that is
sustained for 4 days resulting in 3e4-fold larger pSTAT5a AUCs and
corresponding increases in Tregs and the AUCs of Treg/mm3. In-
termediate levels and duration of pSTAT5a induction result in
moderate increases in Tregs. Following in vivo activation with
Proleukin and IgG-(IL-2)2, Treg cell surface CD25 as well as intra-
cellular FOXP3 and Ki-67, increased in a dose-dependent manner
and persisted longer than the corresponding pSTAT5a responses;
the effects of IgG-(IL-2)2 were >10-fold more potent and persisted
longer than those induced by Proleukin. Of particular signiﬁcance,
the cynomolgus Tregs present after IgG-IL-2 and IgG-(IL-2)2-
induced in vivo expansion retain their fully demethylated FOXP3
and CTLA4 epigenetic signatures indicating a functional suppressive
phenotype. Although we did not directly test the suppressive
Fig. 8. Effects of multiple dose Proleukin and single dose IgG-IL-2. (A, B) Proleukin was given every other day (arrows) at 800 pmol/kg and changes in Tregs/mm3 and memory Teff/
mm3 were assessed as were fold-changes in memory and naïve Tregs. (C, D) pSTAT5a activation in memory and naive Tregs and memory Teff are shown as well as % Ki-67þ cells for
induction into cell cycle. (E) Maximal eosinophil counts are shown for multi-dose Proleukin and IL-2 fusion proteins. (F) The time course of eosinophilia for multi-dose Proleukin
and single-dose IgG-IL-2 (157 pmol/kg) or IgG-(IL-2)2 (34 pmol/kg). (G) Comparison of single and multiple-dose Proleukin with single-dose IgG-IL-2 and IgG-(IL-2)2 for stimulating
Tregs are shown as increases above individual baselines as % of CD4þ T cells. Group sizes were: multi-dose Proleukin (n ¼ 5); IgG-IL-2 (all doses, n ¼ 6); IgG-(IL-2)2 (11 and 34 pmol/
kg, n ¼ 5; 4 pmol/kg, n ¼ 3); and Proleukin (40 and 400 pmol/kg, n ¼ 3; 120 pmol/kg, n ¼ 4).
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induced to expand by Proleukin have been documented to be
functional using in vitro suppression assays in both human [20,21]
and cynomolgus [43,44] studies.Activation and expansion of Tregs by IL-2, most likely in com-
binationwith T cell receptor-driven signaling [45], seems to require
a sufﬁcient magnitude and duration of IL-2 exposure. Although
pSTAT5a levels were not reported, Treg expansion in normal human
C.J.M. Bell et al. / Journal of Autoimmunity 56 (2015) 66e80 79volunteers required daily dosing for ﬁve days with Proleukin and
was clearly dose dependent [23], a ﬁnding that is consistent with
the sustained, suprathreshold effects observed in cynomolgus in
this study given single doses of IgG-IL-2 and IgG-(IL-2)2 or
multiple-doses of Proleukin.
The ability of cynomolgus to respond and differentiate amongst
different forms and doses of IL-2 with varying degrees of activation
and increases in Tregs speaks to their utility as a translational
preclinical species. In fact, single doses of IgG-IL-2 and IgG-(IL-2)2
replicated the increased number of Tregs (Fig. 2A, B) seen in GVHD
patients given daily Proleukin [20]. Furthermore, Proleukin given to
cynomolgus following the same multiple-dose protocol at the hu-
man equivalent dose (Fig. 8F, G) achieved the same increases in
Tregs and eosinophils as patients with type 1 diabetes [35].
The long half-lives of IgG-IL-2 and IgG-(IL-2)2 enable the
detection of receptor-mediated clearance of IL-2 in vivo; the half-
lives of the fusion proteins are ﬁve times longer in mice in the
absence of the high afﬁnity IL-2 receptor (Fig. 2H). The competition
for injected IL-2 by different cell populations and the upregulation
of IL-2 receptors in response to injections of the cytokine [46] are
important considerations when interpreting IL-2 doses required for
preferential Treg expansion.
One limitation of the current study is that cynomolgus NK cells
do not expand in response to IL-2 as readily as humans. Daily
dosing of 1e3 106 units of proleukin increases NK cells in patients
with chronic GVHD and type 1 diabetes [20,24].Withmultiple-dose
Proleukin in cynomolgus the expansion of Tregs and eosinophils
occurs as expected based on humans treated with the equivalent
dosing regimen but not the increase in NK cells [35]. Similar to our
study, therewas no increase in cynomolgus NK cells with 28 days of
daily Proleukin given at levels sufﬁcient to induce a large expansion
of Tregs [43]. It is unclear why cynomolgus NK cells do not expand
following IL-2 dosing, unlike humans and mice [34,35] especially
since the NK cells have high levels of CD122 and can be killed by an
IL-2-immunotoxin (denileukin diﬁtox) [47]. The failure of low-dose
IL-2 to expand cynomolgus NK cells in vivomeans that this aspect of
IL-2 immunotherapy using novel, long-lived molecules will need to
be addressed in future human studies. Despite these differences,
the pharmacokinetic and pharmacodynamic analyses in this cyn-
omolgus study strongly support the hypothesis that increasing the
half-life of IL-2 allows for lower doses of IL-2 to be delivered far less
frequently thereby favoring prolonged Treg-speciﬁc cell expansion.
Ultra-low doses of IL-2 have the potential to personalize treat-
ments for different autoimmune and inﬂammatory diseases as well
as individual patients. The current study illustrates that a wide
range of dose-dependent sustained Treg activation states can be
readily induced by ultra-low dose IgG-(IL-2)2, evidenced by the
pSTAT5a responses as well as CD25, FOXP3 and Ki-67. With dose
selection of a potential therapeutic such as IgG-(IL-2)2, Tregs could
be activated to varying degrees and individualized to generate the
appropriate level of in vivo Treg expansion as the clinical circum-
stances and individual patient responses to treatment dictate.
5. Conclusions
Our results in nonhuman primates show that the development
of long-lived IL-2molecules enables the extended in vivo delivery of
this cytokine that is essential for Treg maintenance and does so in a
manner that minimizes the expansion of eosinophils, effector CD4þ
and CD8þ T cells. By increasing the stoichiometry of IL-2 on the IgG
molecule, e.g. IgG-(IL-2)2, we not only enhanced binding to the IL-2
receptor but generated a molecule with sustained and speciﬁc ef-
fects on Tregs at ultra-low in vivo doses. A striking ﬁnding facili-
tated by the in vivo dose response to IgG-(IL-2)2 was the correlation
between the extent of sustained suprathreshold pSTAT5a inductionin Tregs and the ability to increase the absolute numbers of Tregs/
mm3 in blood. These long-lived IL-2 fusion proteins have the po-
tential to improve IL-2 immunotherapy in conditions where Pro-
leukin has already been shown to provide beneﬁt, GVHD and
hepatitis C-induced vasculitis [20e22], as well as other inﬂamma-
tory and autoimmune conditions.
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